Industry leaders call for a new era of collaboration, innovation, and self-reliance

Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization

Cambrex to invest $120 million to expand API manufacturing in US

Expanding US operations to address the increased demand for API development and manufacturing

HRV Pharma unveils brand mascots

Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership

Fermenta to sell environmental solutions business to its subsidiary

The entity will undertake the installation, operation, and maintenance of sewage treatment plants

Fermenta granted process patent for plant-based Vitamin D3

Aarti Pharmalabs inaugurates phase 1 of greenfield manufacturing facility

Phase 1 has a total reactor capacity of 440 kL with 63 reactors

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL

From Policy to Practice: How India’s Pharmaceutical Industry is Being Shaped by the PLI Scheme – by Vikram Aditya Sehgal, Director – Finance, Centrient India

The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations

Granules India Q1 FY26 PAT slips to Rs. 112.6 Cr